Tofacitinib citrate 540737-29-9 Rheumatoid arthritis Anticancer
Tefo:T/T, L/C
Tšimoloho ea Sehlahisoa:China
Boema-kepe:Beijing/Shanghai/Hangzhou
Bokhoni ba tlhahiso:100kg / khoeli
Odara(MOQ):25kg
Lead time:3 Matsatsi a ho sebetsa
Boemo ba polokelo:E bolokiloe sebakeng se pholileng, se omileng, mocheso oa kamore.
Lintho tsa sephutheloana:moropa
Boholo ba sephutheloana:25kg/moropa
Lintlha tsa polokeho:Eseng thepa e kotsi
Selelekela
Tofacitinib ke moriana o sebelisetsoang ho phekola ramatiki ea lefuba, ramatiki ea psoriatic le lefu la ho ruruha ha ulcerative.
Tofacitinib citrate e sebelisoa ho phekola batho ba baholo ba nang le ramatiki ea ramatiki e sebetsang ka mokhoa o itekanetseng ho isa ho e matla ba bileng le karabelo e sa lekaneng, kapa ba sa mamelleng methotrexate.
Tofacitinib citrate e bontšoa bakeng sa phekolo ea ramatiki ea ramatiki (RA) e leka-lekaneng ho isa ho e matla ho batho ba baholo ba arabetseng ka mokhoa o sa lekaneng, kapa ba sa mamelleng meriana e le 'ngoe kapa tse ngata tse fetolang lefu la antirheumatic.
Tlhaloso (ka tlung)
| Ntho | Tlhaloso |
| Ponahalo | Phofo ea kristale e tšoeu kapa e tšoeu |
| Boitsebiso | IR, HPLC |
| Metsi | ≤1.5% |
| Lintho Tse Amanang | TOFA 06 ≤0.15% |
| Tofacitinib trans isomer ≤0.15% | |
| Tofacitinib dehydrogenated ≤0.15% | |
| Tšilafalo e 'ngoe le e 'ngoe e sa tsejoeng ≤0.10% | |
| Kakaretso ea Litšila: ≤1.0% | |
| Metsoako e setseng | Ethanol ≤5000ppm |
| Benzene ≤2ppm | |
| Toluene ≤890ppm | |
| Chlroroethane ≤1000ppm | |
| N, N-Dimethylformamide ≤800ppm | |
| Palladium ≤10ppm | |
| Dichloromethane ≤600ppm | |
| Molora o nang le sulphated | ≤0.1% |
| Tšepe e boima | ≤10ppm |
| Chrial HPLC | 3S, 4S tofacitinib ≤0.15% |
| Tekolo (ka lebaka la anhydrous) 98.0-102.0% |
